News from eisai inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:ARNA)

Jan 29, 2016, 07:55 ET

FDA Approves Eisai's Halaven® (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate) Injection (0.5 mg per...

Jan 28, 2016, 16:45 ET

FDA Approves Eisai's Halaven® (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate) Injection (0.5 mg per...

Jan 17, 2016, 18:15 ET

Eisai's Lenvatinib Receives FDA Priority Review for the Potential Treatment of Advanced Renal Cell Carcinoma in Combination with Everolimus

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug...

Jan 11, 2016, 19:01 ET
Dec 20, 2015, 19:01 ET

Gemeinsamer Bundesausschuss (G-BA) stellt Ausmaß des Zusatznutzens des Arzneimittels für seltene Erkrankungen Lenvima® (Lenvatinib) fest

Der Gemeinsame Bundesausschuss (G-BA) hat den patientenrelevanten Zusatznutzen von Lenvima® (Lenvatinib) bei der Behandlung von Patienten mit...

Dec 15, 2015, 19:01 ET

Lenvima® (lenvatinib) subventionerat för sköldkörtelcancer

FOR EUROPEAN MEDIA ONLY - NOT FOR AUSTRIAN OR SWISS JOURNALISTS   Från och med den 3 december ingår Lenvima® (lenvatinib) i...

Dec 11, 2015, 01:01 ET
Dec 11, 2015, 01:01 ET

Presentati al San Antonio Breast Cancer Symposium (SABCS) Nuovi Dati che Confermano il Meccanismo di Azione di Halaven® (eribulina) e delle Possibili Combinazioni

DESTINATO ESCLUSIVAMENTE AI MEDIA DELL'AREA EMEA: NON DESTINATO AI GIORNALISTI DI SVIZZERA/STATI UNITI  Nuovi dati confermano la...

Dec 11, 2015, 01:01 ET

Neue Daten zum Wirkmechanismus von Halaven®(Eribulin) und zu möglichen Kombinationsansätzen beim San Antonio Breast Cancer Symposium (SABCS) 2015

PRESSEMITTEILUNG NUR FÜR EMEA-MEDIEN: NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ/DEN USA  Neue Daten belegen die bereits zuvor...

Dec 11, 2015, 01:01 ET

Nuevos Datos Muestran el Mecanismo de Acción de Halaven® (eribulina) y sus Posibles Combinaciones en el Simposio Sobre el Cáncer de mama de San Antonio 2015 (SABCS)

SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA: NO PARA LOS MEDIOS SUIZOS/ESTADOUNIDENSES  Nuevos datos confirman la capacidad previamente...

Dec 09, 2015, 13:35 ET
Dec 09, 2015, 12:54 ET
Dec 09, 2015, 12:43 ET
Dec 09, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human...

Dec 09, 2015, 05:14 ET
Dec 07, 2015, 19:01 ET